- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02550535
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
Single Arm Phase I/II Study of the Safety and Efficacy of Gene-modified WT1 TCR Therapy in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML) Who Have Failed to Achieve or Maintain an IWG Response Following Hypomethylating Agent Therapy
This is a Phase I/II trial to determine safety, clinical efficacy and feasibility of a gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).
Patient's white blood cells (T cells) will be modified by transferring a gene which enables them to make a new T cell receptor (TCR) that can recognize fragments of a protein called WT1 (Wilms' tumour 1) which is present at abnormally high levels on the surface of myelodysplastic and leukaemic cells.
In this trial, approximately 25 participants with an Human Leukocyte Antigen A2 (HLA-A*0201) tissue type who have failed to achieve or maintain an IWG defined response following hypomethylating agent therapy will be recruited.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Phase I/II trial to determine safety, clinical efficacy and feasibility of a gene-modified WT1 TCR therapy. Following provision of informed consent, each subject will undergo screening assessments, including HLA-A*0201 screening (if not already documented) and a bone marrow aspirate/biopsy (BMA) to determine subject eligibility for the trial.
Subjects will undergo leukapheresis within 14 days of screening.
Once successful manufacture of the WT1 TCR-transduced T cells has been confirmed by the Sponsor, each subject will be administered a lymphodepletive conditioning regimen for five days consisting of fludarabine x 5 days 30mg/m2 intravenous (i.v.) and methylprednisolone x 1 day 500 mg i.v. Upon completion of the conditioning regimen, subjects will receive an infusion of WT1 TCR-transduced T cells of ≤2 x 107/kg, followed by daily IL-2 subcutaneous injections (1 x 106 units/m2 subcutaneous (s.c.) od) for 5 days.
If an IWG response has not been reported (one or more criteria met) at 3 months post-infusion then, if agreed by both the Investigator and Sponsor, the subject will be offered to have a repeat infusion of WT1 TCR-transduced T cells.
Following infusion, subjects will enter an intensive period of out-patient follow-up to observe them for any acute complications and toxicities. Subjects will then be followed monthly in the clinic for the first 6 months for routine safety and clinical evaluations, including disease response evaluations. All subjects will be followed-up for a minimum of 12 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Brugge, Belgium, B-8000
- AZ St Jan Brugge-Oostende AV
-
Leuven, Belgium, B - 3000
- UZ Leuven
-
-
-
-
-
Dresden, Germany, 01307
- Uniklinikum Dresden
-
-
-
-
-
Bristol, United Kingdom, BS2 8ED
- University Hospitals Bristol NHS Foundation Trust
-
Leeds, United Kingdom, LS2 9LN
- The Leeds Teaching Hospitals Nhs Trust
-
London, United Kingdom, NW1 2PG
- University College London Hospitals NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion criteria:
- The trial will recruit subjects with MDS or AML who have received hypomethylating agent therapy (at least 6 cycles of azacitidine or 4 cycles of decitabine), and are EITHER:
- Relapsed, defined as failing to maintain an initial IWG response
OR
• Stable, defined as failing to achieve an IWG response
Subjects who have received hypomethylating agent therapy as part of a combination regimen may be eligible after discussion with the Sponsor.
Subjects aged 18 years or older who have a diagnosis of, EITHER:
MDS with an IPSS of intermediate -2, or high and one of the following FAB types:
- Refractory anaemia with excess blasts (RAEB)
- Chronic myelomonocytic leukaemia (CMML) with at least 10% bone marrow blasts (WHO CMML II) OR
- AML (diagnosed according to WHO classification 2008 revision)
- Subjects with documented HLA-A*0201 positive serotype
- Subjects with less than 30 per cent bone marrow blasts
- Subjects with relapsed disease must have less than 5 per cent peripheral blasts
- Subjects with stable disease must have less than 10 per cent peripheral blasts
- Subjects with less than a doubling of bone marrow blast count between the start of hypomethylating agent therapy and the date of screening
- Subjects to complete screen 1 visit within a minimum of 28 days and maximum of 90 days since completion of azacitidine or decitabine therapy. Subjects who have exceeded the 90 day window may be eligible after discussion with the Sponsor.
- Subjects with ECOG status 0, 1 or 2
- Subjects who have at least one cytopenia (ANC <1000/μL, platelet count <75,000/μL, Hgb <11g/dL or RBC transfusion dependence)
Key Exclusion criteria:
improvement or molecular response following azacitidine treatment
- CMML patients who have a white blood cell count > 13 x 109/L
- Acute promyelocytic leukaemia (FAB M3 Classification)
- Uncontrolled intercurrent illness
- Active malignancy, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast
- Known history of Human Immunodeficiency Virus (HIV), Hepatitis C virus (HCV) or Hepatitis B virus (HBV) or positive for Human T-Lymphocyte Virus (HTLV) or Syphilis. • Active auto-immune disease
- Clinically significant non-hematologic toxicity after prior therapy chemotherapy higher than grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) (v 4.0)
- Subjects who require haemodialysis or peritoneal dialysis
- Pregnant and lactating women
- Subjects unwilling or unable to use adequate contraceptive precautions at screening and throughout the trial
- Subjects who have undergone major surgery without full recovery within last 28 days prior to screening
- Subjects with known hypersensitivity to cyclophosphamide, fludarabine, methylprednisolone or IL-2 (Interleukin-2)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gene-modified WT1 TCR-transduced T cells
A single dose of bulk WT1 TCR-transduced T cells (≤ 2 x 107/kg) will be intravenously (i.v.) administered following protocol-specified lymphodepletive conditioning regimen.
Additionally, daily IL-2 subcutaneous injections (1x106 units/m2 subcutaneously (s.c.)) will be administered for 5 days concomitantly to each subject, following infusion of the ATIMP.
|
Gene therapy: Autologous WT1 TCR transduced T cells administered by intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety following gene-modified WT1 TCR T cell therapy as measured by suspected unexpected serious adverse reactions (SUSARS)
Time Frame: 12 Months
|
12 Months
|
Proportion of subjects achieving one or more IWG response criteria following gene-modified WT1 TCR T cell therapy
Time Frame: 12 Months
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of gene-modified WT1 TCR therapy as measured by clinical laboratory parameters and adverse events
Time Frame: 12 Months
|
12 Months
|
|
Efficacy of WT1 TCR therapy as measured by haematological improvement, overall remission rate, marrow remission, cytogenetic response, molecular response, stable disease, AML transformation, progression free, event free and overall survival
Time Frame: 12 Months
|
Haematologic Response (peripheral blood): Haematological response will be assessed by haematology results and capturing data on number of RBC/platelet transfusions given to the subject. Marrow Response: Bone marrow aspirate and/or biopsy morphology results will be recorded and assessed for marrow response in combination with peripheral blood response Cytogenetic response: cytogenetic evaluations will be performed on bone marrow aspirates/biopsies obtained during the trial. Molecular response: molecular profile evaluations will be performed on bone marrow aspirates/biopsies obtained during the trial. Disease response: Investigator will determine response (CR, PR, stable disease (SD), PD/TF) to administration of WT1 transduced T cells based on bone marrow blast count and peripheral blood assessments. Subject disease events, progression and survival will be reviewed, assessed and recorded by the Investigator. |
12 Months
|
Technical feasibility of gene-modified WT1 TCR therapy in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML).
Time Frame: 12 Months
|
12 Months
|
|
Persistence of WT1 TCR-transduced T cells
Time Frame: 12 Months
|
Persistence of infused WT1 TCR-transduced T cells by Vβ2.1 and tetramer staining and PCR for Vβ2.1 and TCR-vector fragments.
|
12 Months
|
Functionality and phenotype of WT1 TCR-transduced T cells
Time Frame: 12 Months
|
Function will be evaluated by measuring antigen-specific intracellular cytokine production in response to target cells that express HLA-A*201 alleles as well as WT1.
Surface differentiation and memory phenotype will be determined using multi-parameter flow cytometry.
|
12 Months
|
WT1 Transcript analysis in AML/MDS cells
Time Frame: 12 Months
|
WT1 overexpression will be used as a measure of disease monitoring on peripheral blood and BMA samples.
RT-qPCR will be used to detect WT1 transcripts.
|
12 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Emma Morris, MD, University College London Hospitals
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D-00272-CT2014002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes (MDS)
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
SCRI Development Innovations, LLCNovartis PharmaceuticalsTerminated
-
PersImmune, IncUniversity of California, San DiegoUnknown
-
Sunnybrook Health Sciences CentrePrincess Margaret Hospital, Canada; Juravinski Cancer CenterUnknownQuality of Life | Myelodysplastic Syndromes (MDS) | Red Blood Cell (RBC) TransfusionsCanada
Clinical Trials on Autologous WT1 TCR transduced T cells
-
Cell Medica LtdUniversity College, London; Cell Therapy CatapultCompletedAcute Myeloid Leukaemia | Chronic Myeloid LeukaemiaUnited Kingdom
-
T-knife GmbHTerminatedAdvanced Solid TumorsGermany, Belgium, Spain, Netherlands, United Kingdom
-
The Netherlands Cancer InstituteUnknownStage IV Skin Melanoma | Eye; MelanomaNetherlands
-
University College, LondonSuspendedCMV Infection | Haematological MalignanciesUnited Kingdom
-
VIRxSYS CorporationActive, not recruitingHIV InfectionsUnited States
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.The First People's Hospital of Hefei; Hefei Binhu HospitalUnknownHepatocellular Carcinoma | Non-small Cell Lung Cancer | Pancreatic Carcinoma | Triple-Negative Invasive Breast CarcinomaChina
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.The First People's Hospital of Hefei; Hefei Binhu HospitalUnknownMalignant Glioma of Brain | Gastric Carcinoma | Colorectal CarcinomaChina
-
Verismo TherapeuticsRecruitingOvarian Cancer | Mesothelioma, Malignant | Cholangiocarcinoma RecurrentUnited States
-
Memorial Sloan Kettering Cancer CenterAtara BiotherapeuticsCompletedLeukemia | Myelodysplastic SyndromeUnited States
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina